Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

Ana Alfonso-Pierola, Marina Diaz Beya, Teresa Bernal, David Valcarcel, Montserrat Arnan, María Luz Amigo, Joaquin Sanchez-Garcia, Raúl Azibeiro Melchor, Blanca Xicoy, Fernando Ramos, Mar Tormo, Joan Bargay, Maria Teresa Cedena Romero, Leonor Arenillas, Jose Francisco Falantes, Ariane Unamunzaga, Lourdes Hermosin Ramos, Maria Diez-Campelo

Blood (2025) 146 (Supplement 1): 3868.

https://doi.org/10.1182/blood-2025-3868

Published: 2025

Journal Articles

Hematologic neoplasms with germline DDX41 variants: Experience from nine spanish centers.

Miguel López-Esteban, Sara Torres-Esquius, Esperanza Tuset, Beatriz Gómez-Horsfield, Susana Vives, Jordi Viñas, Raquel De Paz Arias, Montserrat Arnan, Elena Bechtold, Lucía Pérez-Lamas, Carmen Talarn, Juan Restrepo, Yanira Florido, Ruth Stuckey, Ramon Garcia-Sanz, Ismael Buño, Maria Julia Montoro, Andres Jerez, Carolina Martinez-Laperche

Blood (2025) 146 (Supplement 1): 6744.

https://doi.org/10.1182/blood-2025-6744

Published: 2025

Journal Articles

Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era

Alfredo De La Torre, Claudia Biosca, Felipe Peña-Muñoz, Marta Peña, Julia Ribes-Amoros, Anna Torrent, María Huguet, Merce Aren Jubany, Silvana Novelli, Cristina Fernandez, Raquel Lopez, Lidia Hurtado, Nicolás Real, Montserrat Arnan, Eva Gonzalez Barca, Anna Sureda Balarí, Alberto Mussetti

Blood (2025) 146 (Supplement 1): 2430.

https://doi.org/10.1182/blood-2025-2430

Published: 2025

Journal Articles

Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy.

Felipe Peña-Muñoz, Fernando Molina, Marta Peña, Julia Ribes-Amoros, Anna Torrent, Maria Huguet, Merce Aren Jubany, Silvana Novelli, Cristina Fernandez, Raquel Lopez, Lidia Hurtado, Montserrat Arnan, Eva Gonzalez Barca, Carlota Gudiol, Julia Laporte, Anna Sureda Balarí, Alberto Mussetti

Blood (2025) 146 (Supplement 1): 7711.

https://doi.org/10.1182/blood-2025-7711

Published: 2025

Journal Articles

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Blood (2025) 146 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2025-2084

Published: 2025

Journal Articles

Better discriminative capacity of blast and blast-mol scores in chronic myelomonocytic leukemia (CMML)

Blood (2025) 146 (Supplement 1): 2083.

https://doi.org/10.1182/blood-2025-2083

Published: 2025

Journal Articles

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5232.

https://doi.org/10.1182/blood-2025-5232

Published: 2025

Journal Articles

Efficacy and safety of CPX-351 in high-risk Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5231.

https://doi.org/10.1182/blood-2025-5231

Published: 2025

Journal Articles

Prognostic implications of commutational patterns in NPM1-mutated AML receiving intensive treatment. cetlam group study

Blood (2025) 146 (Supplement 1): 5274.

https://doi.org/10.1182/blood-2025-5274

Published: 2025

Journal Articles

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Blood (2025) 146 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2025-4275

Published: 2025

Journal Articles

Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated Results from an ongoing Phase 2 trial

Lynette Chee, Shuhying Tan, David Valcarcel, Anish Puliyayil, Alejandro Arbelaez, Montserrat Arnan, David Ross, Devendra Hiwase, Teresa Bernal, Thomas Cluzeau, Aristoteles Giagounidis, Jen Salstrom, Radha Ramesh, Camden Bay, Kevin Galinsky, Leopold Sellner, Kaveri Suryanarayan, Maria Diez-Campelo

Blood (2025) 146 (Supplement 1): 787.

https://doi.org/10.1182/blood-2025-787

Published: 2025

Journal Articles

Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights

Rosa Coll, Nuria Brey, Antonella Luciana Sturla, Jordi Viñas, Montserrat Arnan, Helena Pomares, Susana Vives, Anna Sureda Balarí, Juan-Manuel Sancho, David Gallardo

Blood (2025) 146 (Supplement 1): 6896.

https://doi.org/10.1182/blood-2025-6896

Published: 2025

Journal Articles

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Blood (2024) 144 (Supplement 1): 2874.

https://doi.org/10.1182/blood-2024-200280

Published: 2024

Journal Articles

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Pau Montesinos, Montserrat Arnan, Stephane De Botton, Maria Calbacho, Rebeca Rodriguez Veiga, Pierre Bories, Belén Ansoleaga, Thomas Hueso, Naval Daver, Lydia Wunderle, Andreas Harstrick, Kerstin Pietzko, Pallavi Hajela, Alexandra Vasile, Tania Witte, Elmarie Saenger, Christian Récher

Blood (2024) 144 (Supplement 1): 738.

https://doi.org/10.1182/blood-2024-194356

Published: 2024

Journal Articles

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Blood (2024) 144 (Supplement 1): 1838.

https://doi.org/10.1182/blood-2024-205407

Published: 2024

Journal Articles

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 6167.

https://doi.org/10.1182/blood-2024-203130

Published: 2024

Journal Articles

Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Blood (2024) 144 (Supplement 1): 597.

https://doi.org/10.1182/blood-2024-207189

Published: 2024

Journal Articles

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Blood (2024) 144 (Supplement 1): 4591.

https://doi.org/10.1182/blood-2024-208186

Published: 2024

Journal Articles

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Annalisa Paviglianiti, Marta Bellver Sanchis, Marta Peña, Inmaculada Peiro Martinez, Felipe Peña, Lidia Hurtado, Raquel Lopez Gil, Alberto Mussetti, Montserrat Arnan, Helena Pomares, Eva Gonzalez Barca, Patricia Lopez Pereira, Rocky Strollo, Paolo Pozzilli, Anna Sureda Balari

Blood (2024) 144 (Supplement 1): 7412.

https://doi.org/10.1182/blood-2024-198124

Published: 2024

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

Hematologic neoplasms with germline DDX41 variants: Experience from nine spanish centers.

Comorbid but transplantable: Favorable outcomes with RIC and ptcy in patients with an HCT-CI score of 3 or higher in the modern era

Letermovir primary prophylaxis is associated with reduced and delayed CMV reactivation in haploidentical allohct using ptcy.

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Better discriminative capacity of blast and blast-mol scores in chronic myelomonocytic leukemia (CMML)

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Efficacy and safety of CPX-351 in high-risk Acute Myeloid Leukemia

Prognostic implications of commutational patterns in NPM1-mutated AML receiving intensive treatment. cetlam group study

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated Results from an ongoing Phase 2 trial

Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights

A Multicenter, Prospective, Non-Randomized, Phase I-II Trial to Asses the Efficacy and Safety of the Combination or Oral Quizartinib and the FLAG-IDA Chemotherapy Regimen in First Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Hematologic Improvement and Fatigue Reduction with Elritercept (KER-050) in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS) with Non-Transfusion Dependent Anemia: New Analyses from an Ongoing Phase 2 Trial

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only